Immunology
CiMaas, a developer of cellular immunotherapy for cancer, and PharmaCell, a contract manufacturer for cellular therapies and regenerative medicine in Europe, are collaborating in the clinical development of CiMaas’ products.
Under the agreement, PharmaCell will provide consulting services on writing GMP-compliant documents for the purpose of translating the CiMaas cell therapy processes into GMP. Options have been taken on a full technology transfer trajectory to be started and executed at a later date. A continuation option on a Phase I and possibly a Phase II clinical trial is also part of the agreement.
Gerard Bos, chief executive officer of CiMaas, said: “We are delighted to collaborate with PharmaCell and receive support in building our documents and technology in a fully GMP compliant manner for the development of our ATMPs (advanced therapy medicinal products).”
Alexander Vos, chief executive officer of PharmaCell, said: “The CiMaas team has shown to be successful in bringing their technology to the point of preparing the initiation of clinical studies. We are excited to support them to make their production process GMP-compliant and help clear the path to bring their innovative therapies to benefit patients."